Context: Sepsis is associated with high mortality and treatment costs. International guidelines recommend the implementation of integrated sepsis protocols; however, the true cost and cost-effectiveness of these are unknown.
T he sepsis syndromes are lethal and expensive conditions, with hospital case mortality rates for severe sepsis ranging between 30% and 50% (1) (2) (3) (4) (5) (6) . In the United States, this results in an estimated 751,000 cases and 215,000 deaths annually (1) . Despite advances in medical care, the overall mortality rate for sepsis has improved only slightly over time (2) . Be-yond the human costs, treatment of these patients involves an economic cost estimated at $16.7 billion annually (1) .
After years of disappointing clinical trials in severe sepsis, several new therapies recently have been reported to improve outcomes. Early goal-directed therapy (EGDT), drotrecogin alfa, lowdose steroid therapy, tight glucose control, and low-tidal volume ventilation have demonstrated mortality reduction in large randomized, controlled trials (3) (4) (5) (6) (7) . The integration of these multiple interventions into clinical practice has, however, proven to be a challenge. One proposed solution has been the development of integrated protocols, combining these interventions into one sepsis treatment "bundle." A number of critical care societies have joined with the Institute for Healthcare Improvement in the Surviving Sepsis Campaign to propose widespread adoption of such a bundle (8) . The campaign advocates a program of education, practice im-provement, and performance measurement aimed at improving care through adoption of all of these best practices in sepsis (8) . Although compliance with the sepsis bundles proposed by the campaign is not a trivial task, previous studies demonstrate that patients treated using these bundles have improved outcomes (9) .
The interventions comprising the sepsis bundles may greatly influence patients' survival and quality of life. Many of these treatments, however, are extremely time, resource, or cost intensive. Therefore, it is important to understand the costs as well as the consequences associated with these interventions, both individually and as an integrated bundle. Cost-effectiveness analyses have become an increasingly common tool to aid decisions about the allocation of scarce healthcare resources (10, 11) . The huge societal investment in critical care medicine makes these evaluations particularly important (10, 12) . Even if all of the interventions within the sepsis bundle were individually shown to be costeffective, the costs and effectiveness of the complete bundle still need to be demonstrated before widespread adoption can be recommended.
We recently have reported on the results of an integrated sepsis protocol, the Multiple Urgent Sepsis Therapies (MUST) protocol (13) . The components of this protocol are similar to the Surviving Sepsis bundles (14) . Adoption of this protocol led to a mortality reduction. However, economic evaluations of such treatment protocols have not been reported. The purpose of this study is to estimate the cost and cost-effectiveness of the MUST protocol, an integrated sepsis protocol, from a U.S. healthcare system perspective. Information from this study should inform clinicians and policymakers considering adopting similar protocols.
METHODS
Design and Setting. This is an economic analysis of a prospective cohort study of patients who underwent the intervention of the MUST protocol, a comprehensive EGDT-based sepsis treatment pathway. The setting was the emergency department and intensive care units (ICUs) of the Beth Israel Deaconess Medical Center in Boston, MA, an urban, academic teaching hospital with 490 total and 66 dedicated ICU beds. The center has approximately 46,000 emergency department visits and 4,100 ICU admissions annually. The MUST protocol has been described previously and includes patients with a presenting diagnosis of septic shock as well as patients who were enrolled in the protocol for an elevated lactate (13) . The MUST study collected patients between November 10, 2003, and November 9, 2004. To compare similar populations, in this analysis we include only those patients enrolled with septic shock and compare them to historical controls. The historical controls are from a cohort of prospectively collected patients presenting to the emergency department between February 1, 2000, and January 31, 2001, with infection as evidenced by a clinician ordering a blood culture. This cohort was prospectively collected as part of another investigation (15) . This cohort was chosen as the control group because it was largely collected before the publication of the EGDT trial by Dr. Rivers and colleagues (6) . We use this subset for comparison because lactate screening was not routine in the control period. Initial power calculations (power ϭ 0.8; type-1 error ϭ 0.05) estimated 260 patients were needed to detect 15% mortality reduction, assuming a control group mortality rate of 45% (based on the Rivers control group). However, during our planned 1-yr interval analysis, we found that our preprotocol mortality was only 29%. We repow-ered the study for a baseline 29% mortality, showing that an estimated 928 patients would be needed to show mortality benefit. Therefore, because of enrollment constraints for a single-center study, we closed the cohort and reported the results. The study protocol was approved by the institution's Investigational Review Board and granted a waiver of informed consent.
The MUST Protocol. The MUST protocol is an integrated sepsis protocol that utilizes the treatments of a) EGDT; b) antibiotics; c) steroids in adrenal suppression; d) assessment for activated protein C therapy; e) tight glycemic control; and f) low tidal volume ventilation for patients with acute lung injury. Not all patients received all treatments, but the MUST protocol provides for evaluation of each patient for each component of the protocol. Eligible patients were adult medical patients with a) suspected infection; b) Նtwo systemic inflammatory response syndrome criteria; and c) systolic blood pressure Ͻ90 mm Hg after a fluid challenge. Exclusion criteria were: prehospital cardiac arrest, comfort measures only or did not consent to central venous access, indication for immediate surgery, and contraindication to the placement of an internal jugular or subclavian catheter or did not have one initially placed for resuscitation. Patients with do-not-resuscitate orders were included if they requested aggressive medical treatment. A flow diagram outlining the MUST protocol is presented in the Appendix.
Data Collection. Demographic, comorbid conditions, vital sign, physical examination, and laboratory data were collected. Baseline severity-of-illness scores were calculated, including the Acute Physiology and Chronic Health Evaluation (APACHE) II and Mortality in Emergency Department Sepsis (MEDS) scores. These scores were calculated as originally described, except that for the APACHE II score we considered time 0 to be emergency department triage rather than ICU admission.
Survival After Hospital Discharge. As the longitudinal evidence for long-term survival of septic-shock patients is lacking, we estimated the age and gender specific life expectancy for each hospital survivor using the U.S. 2002 life-table data (16) . We then adjusted that life expectancy using the estimated relative risk of death for sepsis survivors (0.51), as reported by Dr. Quartin and colleagues (17) . We have followed the approach for assessing long-term outcomes in critical care that has been used in recent cost-effectiveness analyses (18, 19) . To illustrate, consider a 60-yr-old hospital survivor. The average life expectancy for a 60-yr-old American male is 20.2 yrs. However, by multiplying 20.2 yrs by 0.51 we predict that the 60-yr-old survivor will live only 10.3 yrs. Life years gained were then discounted at a 3% annual rate.
Quality-adjusted Life Expectancy. We adjusted life expectancy for quality of life using health state utility weights. Utilities represent an individual patient's preference for a given health state and are usually scaled from 0 (representing death) to 1 (representing perfect health). Because quality of life following an episode of severe sepsis and septic shock may be diminished, we used an estimate of 0.69 for a typical severe sepsis survivor to calculate quality-adjusted life expectancy (QALY) (20, 21) . This value was derived from a previous study of 93 severe sepsis survivors over a 6-month period using the EuroQol Group's EQ-5D instrument (20, 22) and has been used in a previous cost-effectiveness analysis. To generate the QALY for each hospital survivor, we multiplied this utility value by the adjusted discounted life-expectancy. We did not assign utility decrements for the acute treatment period in the hospital, because a patient's quality of life during the hospital stay has only a marginal effect on the results of our analysis.
Costs. All in-hospital treatment costs were collected using the hospital's detailed accounting system, calculated for each hospital's cost center and presented in 2004 U.S. dollars. Costs in the historical control cohort were adjusted to year 2004 values using the medical component of the Consumer Price Index, and multiplied by 1.17 to reflect the addition of physician costs (19) . The costs of implementing the protocol consisted largely of staff training. This was done within the framework of ongoing continuing medical education, and therefore these costs are ignored. In our analysis, we did not include costs incurred after hospital discharge, because we have no data on postdischarge costs that could be attributed to patients surviving a septic shock episode. Thus, treatment costs were not discounted. Given that we took the perspective of a thirdparty payer, we did not include in our analysis indirect costs, such as productivity loss and other nonmedical expenses.
Statistical Analysis. Discrete data are reported as frequencies, and continuous data are reported as mean Ϯ standard deviation (SD). Discrete variables were compared by chi-square test. Normally distributed continuous variables were compared by Student's t-test, whereas non-normally distributed data were compared by Wilcoxon's rank-sum test. Because of the skewed distribution of costs, we assessed the difference between the treatment groups and the 95% confidence intervals (CIs) for the mean difference using nonparametric bootstrapping, drawing 1,000 samples with replacement of the same size as the original samples of patients. We used the same approach to calculate the differences in life expectancy and QALY between the treatment and the control groups. Finally, we estimated the proportion of the joint distribution of cost and effectiveness differences lying in different regions of the cost-effectiveness plane (23) .
Calculation of Incremental Cost-effectiveness Ratios. The cost-effectiveness analysis was performed from the perspective of a thirdparty payer using a lifetime horizon. The primary end point for the cost-effectiveness anal-ysis was the incremental cost per QALY gained. This ratio was calculated by dividing the average difference in costs of treating a patient in the MUST protocol vs. usual care (C MUST Ϫ C usual care ), as determined by the bootstrap method, by the difference in QALYs gained (E MUST Ϫ E usual care ), determined using the same approach. We also report the incremental cost per life year gained.
To account for uncertainty due to sampling variation in cost-effectiveness, we plotted a cost-effectiveness acceptability curve showing the probability of the MUST protocol being more cost-effective than the conventional treatment for different maximum levels for societal willingness to pay for an additional QALY (24) .
Sensitivity Analysis. Sensitivity analyses were performed to examine the impact of alternative assumptions regarding life expectancy and relative risk of death for sepsis survivors, utility weights, and discount rate. In our base case analysis, we applied a relative risk of death of 0.51 to the projected life expectancy of all hospital survivors. Given that patients in our study survived septic shock, we applied in our sensitivity analysis a worse penalty of 0.39 to all patients, similar to the approach used by Dr. Angus and colleagues (19) . This estimate was derived from Dr. Quartin and colleagues (17) and represents the increased risk of death in patients developing septic shock.
In our analysis, we used a utility weight of 0.69 for post-sepsis survivors. However, because data on quality of life for septic shock survivors is limited, other scholars have used utility weights derived from similar conditions. For example, Dr. Manns and colleagues (26) used a utility value of 0.6 to estimate the health-related quality of life after hospital discharge. This utility weight was derived from a group of patients admitted to the ICU with an acute respiratory distress syndrome, and was assumed to be similar to sepsis patients in terms of the severity of illness. Dr. Fowler and colleagues assumed (27) that the utility weight of post-sepsis survival is 0.8, which equals the utility weight after similar acute illnesses. Dr. Angus and colleagues (25) reported an average utility of 0.68 for severe sepsis survivors. Finally, we generated a cost-effectiveness ratio without discounting patient's life expectancy. We used the $50,000 and $100,000 thresholds to calculate the probability that the MUST protocol was cost-effective (i.e., falls below these thresholds). These figures represent the prevailing thresholds for determining "good value for money" in cost-effectiveness analyses (28) .
RESULTS
Patient Characteristics. There were 79 patients with septic shock in the treatment cohort and 51 patients in the control group. Patient main demographic and clinical characteristics are presented in Table 1 . Mean age of patients was 69.5 Ϯ 16.1; 45% were male and the mean APACHE II score was 24.2 Ϯ 9.5. None of these baseline characteristics differed significantly between the treatment and control groups. Table 1 also outlines the treatments actually delivered to the patients in each cohort. These findings have been reported and discussed previously (13) .
Base Case Analysis. The estimated clinical and cost outcomes associated with treating patients according to the MUST protocol and conventional ther-apy are presented in Table 2 . All cost and life expectancy estimates are based on a bootstrap analysis with 1,000 replicates. The total mean discounted cost per patient treated with the MUST protocol was $38,569 (95% CI, $38,259 -$38,879) vs. $29,762 (95% CI, $29,349 -$30,176) for patients in the control group. Implementing the MUST protocol resulted in a mean increase of $8,807 (95% CI, $8,276 -$9,338) per patient, which was largely driven by increased ICU length of stay and increased pharmacy costs (Fig. 1) .
Mortality in the MUST group was 20.3% vs. 29.4% in the control group (p ϭ .29). The average discounted life expectancy of patients treated with the MUST protocol increased by 0.78 yrs (95% CI, 0.73-0.84). Thus, without adjustment for quality of survival, imple- menting the MUST protocol cost $11,274 per life year gained. After adjusting for quality of survival, using the MUST protocol resulted in a discounted qualityadjusted life expectancy increase of 0.54 (95% CI, 0.50 -0.58), and a cost of $16,309 per QALY gained. The MUST protocol was dominated (i.e., resulting in higher costs and lower life expectancy) in 15.9% of the bootstrap simulations and dominant (i.e., resulting in lower costs and higher life expectancy) in 13.6% of simulations ( Fig. 2A) . The cost-effectiveness acceptability curve is presented in Figure 2B and indicates that the higher the value that decisionmakers are willing to pay for an additional QALY, the higher the probability that the MUST protocol will be more cost-effective than conventional therapy. For example, at a maximum value of $50,000 the probability is 72.6%, and at a maximum value of $100,000 the probability is 78.0%. Applying different values of utility weights for survivors resulted in an incremental cost-effectiveness ratio of $54,975/QALY when the worse quality of life was assumed and $11,264/QALY when a perfect quality of life was assumed (Fig.  3) . When life years gained and QALYs were not discounted, patients treated with the MUST protocol gained on average 0.96 life years and 0.66 QALYs, resulting in a cost-effectiveness ratio of $9,174 per life yr gained, and $13,334 per QALY gained.
DISCUSSION
The major finding of this study is that adoption of an integrated sepsis protocol was associated with increased in-patient survival at a moderate increase in treatment costs. The cost for treating a patient in an integrated sepsis protocol was approximately $8,800 greater than for patients treated before institution of such a protocol. These increased costs in the study cohort largely were driven by higher ICU costs associated with increased ICU length of stay. The ICU length of stay was increased among both survivors and nonsurvivors. This is certainly plausible-we would expect that the people "saved" by EGDT would require a longer ICU length of stay than if they had died earlier in their course. In addition, we would expect that some patients would be kept alive longer by EGDT but would eventually die. They too would have a longer ICU length of stay. It is notable that in the entire group of patients, the four patients with the longest ICU length of stay (27, 34, 35 , and 59 days) received the MUST protocol and all survived.
Defining whether a therapy is costeffective or not requires a judgment about society's willingness to pay for a QALY or life year gained. Although there is no absolute cutoff, an incremental cost-effectiveness ratio of $50,000 to $100,000 per year of life gained is generally considered a good value for money in the United States today (28) . Our base case estimate is that implementing the MUST protocol costs $16,309 per QALY gained, and $11,264 per life year gained. These cost-effectiveness ratios are similar to, or better than, those for many healthcare strategies used in U.S. ICUs (29) . For example, Dr. Angus and colleagues (19) found that using drotrecogin alfa (activated) in the treatment of severe sepsis costs $48,800 per QALY gained, and $33,300 per life year gained. Even when long-term costs were not included (similar to our base case), the cost-effectiveness ratio was $29,800 per QALY gained. (30) . Although an economic evaluation was not presented, the results from this study may suggest that a standardized treatment protocol is both more effective and cost saving. The MUST protocol is a prospectively studied integrated sepsis protocol that showed a relative risk reduction for mortality reduction of 31%. This is consistent with the expected benefit of adoption of the Surviving Sepsis bundles and with several other studies that have shown relative risk reductions of between 31% and 39% (6, 30, 31) . Our study was on the lower end of this range. The costeffectiveness of an integrated sepsis protocol would only improve as the relative risk reduction increases. Similarly, the cost-effectiveness of a sepsis protocol will be influenced by the baseline mortality from septic shock before the intervention. In the MUST study, the observed 31% relative risk reduction in mortality was not significant because of relatively low baseline mortality at our institution and a small sample size.
Our study has several important limitations attributed to the design and results of the clinical study. The first and foremost is the lack of a randomized design; we compared prospectively enrolled patients with a historical cohort of patients treated for septic shock. Although this may affect the internal validity of our analysis, patients treated by the MUST protocol and historical controls were similar in most of their demographic and clinical characteristics, relevant to the cost-effectiveness analysis; however, we cannot account for unmeasured confounders. Second, the mortality rate of patients in our study was significantly lower then in other published studies looking at the treatment of patients with septic shock. Although MUST protocol patients benefited from an absolute reduction in mortality of 9.1% and a relative risk reduction of 31%, our study was underpowered to detect statistically significant mortality benefits. Nevertheless, according to the economic literature it is inappropriate to conclude that the lack of statistically significant difference in mortally between MUST patients and the historical controls implies that the difference in mortality is zero (32) . The difference between the two treatment groups remains the best estimate of effect difference. Therefore, conducting a cost-effectiveness analysis was still appropriate (32) .
Third, this is a single-center study and thus requires validation in other centers and other healthcare systems to test the generalizability of our findings. Finally, our analysis is limited to patients with septic shock on presentation to the emergency department. We have not examined the results of our protocol on patients with the other sepsis syndromes.
Several other limitations relate to the economic component of our study. First, because patients were not followed beyond hospital discharge, we did not have data on long-term costs and these costs Quadrants to the right of the y-axis represent regions where treating patients with the MUST protocol in associated with net QALYs gained. Quadrants above the x-axis represent regions where the Multiple Urgent Sepsis Therapies (MUST) protocol is associated with a net increase in cost. The dashed and the solid lines represent the $50,000/QALY and $100,000/ QALY threshold, respectively. Regions below and to the right of the line have a more favorable cost-effectiveness ratio than regions above and to the left of the threshold. B, cost-effectiveness acceptability curve for the MUST protocol vs. conventional therapy. The curve indicates that the higher the value decision-makers are willing to pay for an additional QALY, the higher the probability that the MUST protocol will be more cost-effective than conventional therapy.
were not included in our analysis. However, evidence from other studies suggests that even when long-term costs were included, the cost-effectiveness ratio remains very attractive. For example, Dr. Angus and colleagues (19) estimated that the annual discounted long-term cost for a severe sepsis survivor is approximately $11,500 per life year saved and ‫000,71$ف‬ per QALY saved. Using these estimates in our analysis would have increased the cost-effectiveness ratio from ‫000,11$ف‬ to ‫000,02$ف‬ per life year gained and from ‫000,61$ف‬ to ‫000,52$ف‬ per QALY gained. Second, we projected survival based on the age and sex of individual survivors and used an average estimated "penalty" (0.51) for patients surviving sepsis and septic shock. Because long-term follow-up of septic shock survivors was not available, our base case penalty estimate is based on a study by Dr. Quartin and colleagues (17) in survivors of sepsis. Nevertheless, using a more conservative assumption and applying a worse penalty (0.39) to all hospital survivors had a relatively low impact on the incremental cost-effectiveness ratio, which remains very attractive. Applying no penalty for survivors would only improve our costeffectiveness. Additionally, quality of life estimates for patients surviving a septic shock episode are not available in the literature. Therefore, we used estimates from patients surviving a hospital admission for severe sepsis. Varying this estimate in the sensitivity analysis did not alter substantially our cost-effectiveness results. Finally, although our cost analy-sis is based on real costs, rather than charges or reimbursements, these costs were derived from a single medical center. Costs in other settings may be higher or lower, with a possible impact on costeffectiveness results.
To the best of our knowledge, our study is the first to present the costeffectiveness of an integrated sepsis protocol. Our study of the cost-effectiveness of the MUST protocol indicates that these bundles, while not cost saving, do fall within generally accepted standards of cost-effectiveness.
